Talk:Abiraterone acetate

message: No structure is shown for this article. It is here:
http://www.chemspider.com/Search.aspx?q=Abiraterone--ChemSpiderMan (talk) 00:18, 25 January 2008 (UTC)
replies: text: Added.  -- Ed (Edgar181) 15:49, 25 January 2008 (UTC)
replies: text: Edgar...please check the name. I think it is: (3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(3-pyridinyl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol--ChemSpiderMan (talk) 16:05, 25 January 2008 (UTC)
replies: text: I just copied the one at the PubChem link.  I don't know how to judge which is more appropriate, so feel free to use whichever you feel is best.  -- Ed (Edgar181) 16:08, 25 January 2008 (UTC)
thread_title: Chemical structure

message: "In the UK, despite being licensed by the European Medicines Agency,[15] the drug is not currently[when?] available for routine use on the NHS. In February 2012, the National Institute for Health and Clinical Excellence (NICE) issued[16] preliminary guidance that the drug will not be made available on cost-effectiveness grounds, but this decision is open to consultation.[17] The decision was reversed in May 2012.[18][19][20][21][22][23][24]"
This sentence needs cleaning up.
http://scienceblog.cancerresearchuk.org/2012/05/16/abiraterone-now-available-on-the-nhs-except-in-scotland/  — Preceding unsigned comment added by 87.237.64.150 (talk) 10:47, 28 May 2014 (UTC)
thread_title:  NHS Availability 

message: For the “Adverse Effects” section, there is an opportunity to increase the accuracy and completeness of
the information available on adverse reactions by referring to the following source:
ZYTIGA® (abiraterone acetate) [package insert]. Horsham, PA: Janssen Biotech, Inc.
http://www.zytigahcp.com/full-prescribing-information. 
For the "Interactions" section, there is an opportunity to increase the accuracy and completeness of
the information available on interactions by referring to the following source:
ZYTIGA® (abiraterone acetate) [package insert]. Horsham, PA: Janssen Biotech, Inc.
http://www.zytigahcp.com/full-prescribing-information. {{Lflaiz (talk) 14:46, 13 August 2014 (UTC)
thread_title:  Source 

message: The cited Medscape article (after one clicks tot he Interactions page) does not support the claim that ketoconazole and other CYP17 inhibitors should be avoided. The rationale for that claim also makes little sense. Both abiraterone and those agents are inhibitors. Abiraterone isn't a substrate.  — Preceding unsigned comment added by 73.223.123.144 (talk) 22:38, 21 September 2017 (UTC)
thread_title: Chemical structure

message: I propose that this Abiraterone acetate be merged with Abiraterone. The majority of the latter consists of explanation of the active metabolite. According wikipedia notability guidelines, it makes the most sense to have a single article on the therapeutic agent, with appropriate redirect and short article content on the prodrug.  Admittedly, I have limited experience with editing pharmacology pages, so I welcome justifications for keeping these pages separate. Dr G (talk) 20:26, 13 January 2018 (UTC)
replies: text: Thanks for your note. The prodrug is what is administered as the drug.  Abiraterone acetate is also the International nonproprietary name (INN), and per WP:PHARMMOS, the article title should be the INN.  Therefore if there is any merger, it should be in the other direction.  However I believe that they should be kept separate (different compounds, different articles).  Abiraterone acetate should be main article whereas abiraterone should concentrate on the chemical and in vitro properties of the active metabolite. Boghog (talk) 21:52, 13 January 2018 (UTC)
replies: text:  Thanks for your response. This helps me better understand dealing with pharma articles. I will retract my proposal. Dr G (talk) 21:00, 14 January 2018 (UTC)
thread_title:  Merger proposal 

message: Low-fat meal enhances efficacy of reduced-dose abiraterone for prostate cancer seems hugely significant for this drug. May need to look for a few more sources and discussion on this to see if this report is a fair summary. - How will medics, insurers, FDA, EU etc react ? - Rod57 (talk) 10:43, 11 April 2018 (UTC)
thread_title:  Lower cheaper dose may be possible with some food 

message: The text says take with food. I am sure this is incorrect, but I only added /citation needed/. My bad. ( Martin |  talk • contribs  05:45, 3 December 2018 (UTC)
thread_title:  yes, in connection with the above comment, take on an empty stomach for the 1000mg dosage 

message: I have moved this article to the INN which is "abiraterone". Having separate articles for "abiraterone" and "abiraterone acetate" does not make sense. We have hundreds of medications like atorvastatin calcium which should go to atorvastatin to prevent confusing our readers. The various salts can generally be disused in one spot. Doc James (talk · contribs · email) 11:59, 15 November 2019 (UTC)
thread_title: INN